With Eye On China, India Tightens Foreign Investment Vetting
India revises foreign direct investment rules to bridle any attempts at opportunistic M&A amid the COVID-19 crisis. The move is seen largely targeted at China, though pharma experts have mixed views on the new screening measures.
You may also be interested in...
Join Anju Ghangurde and Vibha Ravi in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series on COVID-19: Lessons Learned And A Path Forward.
With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.
Join the Pink Sheet and Scrip's Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.